{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T13:52:49Z","timestamp":1781963569894,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04462-x","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T13:38:19Z","timestamp":1781962699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of SBRT as an ablative treatment in oligometastatic patients"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-4810","authenticated-orcid":false,"given":"Beatriz","family":"Deb\u00e9n M\u00e9ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6845-643X","authenticated-orcid":false,"given":"Marta","family":"Rodr\u00edguez Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1598-2789","authenticated-orcid":false,"given":"Maria Isabel","family":"Garrido Botella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0943-6399","authenticated-orcid":false,"given":"Mercedes","family":"Gonz\u00e1lez Cantero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1719-622X","authenticated-orcid":false,"given":"Macarena","family":"Teja Ubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9814-2642","authenticated-orcid":false,"given":"Alonso","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rosel Aller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7726-2338","authenticated-orcid":false,"given":"Bel\u00e9n","family":"Belinch\u00f3n Olmeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Miralles Olivar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-9113","authenticated-orcid":false,"given":"Luis Alberto Glar\u00eda","family":"Enriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2080-680X","authenticated-orcid":false,"given":"Aurea","family":"De Manso De Lema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7505-8176","authenticated-orcid":false,"given":"Victor","family":"Duque Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2073-4741","authenticated-orcid":false,"given":"Jes\u00fas","family":"D\u00edez Sebasti\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-8156","authenticated-orcid":false,"given":"Elisabet","family":"Gonzalez Del Portillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"1","key":"4462_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8.","journal-title":"J Clin Oncol"},{"key":"4462_CR2","doi-asserted-by":"crossref","unstructured":"Willmann J, Vlaskou Badra E, Adilovic S, Christ SM, Ahmadsei M, Mayinger M, et al. Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease. Clin Transl Radiat Oncol. 2022;37:12. Available from: \/pmc\/articles\/PMC9421088\/. Accessed 29 Sep 2024","DOI":"10.1016\/j.ctro.2022.08.008"},{"key":"4462_CR3","doi-asserted-by":"crossref","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21(1):e18\u201328. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31908301\/. Accessed: 1 Sep 2022","DOI":"10.1016\/S1470-2045(19)30718-1"},{"key":"4462_CR4","doi-asserted-by":"crossref","unstructured":"Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020; 148:157\u201366. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32388150\/. Accessed: 1 Sep 2022","DOI":"10.1016\/j.radonc.2020.04.003"},{"issue":"5","key":"4462_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2023.101238","volume":"8","author":"A Piening","year":"2023","unstructured":"Piening A, Al-Hammadi N, Dombrowski J, Hamilton Z, Teague RM, Swaminath A, et al. Survival in metastatic renal cell carcinoma treated with immunotherapy and stereotactic radiation therapy or immunotherapy alone: a national cancer database analysis. Adv Radiat Oncol. 2023;8(5):101238.","journal-title":"Adv Radiat Oncol"},{"issue":"18","key":"4462_CR6","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Jack Lee J, et al. Local consolidative therapy vs Maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558\u201365.","journal-title":"J Clin Oncol"},{"key":"4462_CR7","doi-asserted-by":"crossref","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie A V., Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019; 393(10185):2051\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30982687\/. Accessed 28 Jun 2020","DOI":"10.1016\/S0140-6736(18)32487-5"},{"key":"4462_CR8","doi-asserted-by":"crossref","unstructured":"Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28973074\/. Accessed 29 Sep 2024","DOI":"10.1001\/jamaoncol.2017.3501"},{"key":"4462_CR9","doi-asserted-by":"crossref","unstructured":"Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized Trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer. JNCI J Natl Cancer Inst; 115(6):742. Available from: \/pmc\/articles\/PMC10248839\/. Accessed 29 Sep 2024","DOI":"10.1093\/jnci\/djad084"},{"key":"4462_CR10","unstructured":"Role of SRS\/SBRT in oligometastatic disease. - Google Libros. Available from: https:\/\/books.google.es\/books\/about\/Role_of_SRS_SBRT_in_Oligometastatic_Dise.html?id=H0-xzwEACAAJ&redir_esc=y. Accessed 29 Sep 2024"},{"key":"4462_CR11","doi-asserted-by":"crossref","unstructured":"Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010;76(2):326\u201332. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20117285\/","DOI":"10.1016\/j.ijrobp.2009.09.042"},{"key":"4462_CR12","doi-asserted-by":"crossref","unstructured":"Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23276369\/","DOI":"10.1016\/S1470-2045(12)70510-7"},{"key":"4462_CR13","doi-asserted-by":"crossref","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie A V., Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020;38(25):2830\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32484754\/","DOI":"10.1200\/JCO.20.00818"},{"key":"4462_CR14","doi-asserted-by":"crossref","unstructured":"Cao Y, Chen H, Sahgal A, Erler D, Badellino S, Biswas T, et al. The impact of local control on widespread progression and survival in oligometastasis-directed SBRT: Results from a large international database. Radiother Oncol. 2023;186. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37385379\/","DOI":"10.1016\/j.radonc.2023.109769"},{"issue":"5","key":"4462_CR15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, DeBruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446\u201353. https:\/\/doi.org\/10.1200\/JCO.2017.75.4853.","journal-title":"J Clin Oncol"},{"key":"4462_CR16","doi-asserted-by":"crossref","unstructured":"Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021;22(12):1732\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34717797\/","DOI":"10.1016\/S1470-2045(21)00528-3"},{"issue":"4","key":"4462_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ijrobp.2022.08.027","volume":"114","author":"H Kim","year":"2022","unstructured":"Kim H, Venkatesulu BP, McMillan MT, Verma V, Lin SH, Chang JY, et al. Local therapy for oligoprogressive disease: a systematic review of prospective trials. Int J Radiat Oncol. 2022;114(4):676\u201383.","journal-title":"Int J Radiat Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04462-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04462-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04462-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T13:38:28Z","timestamp":1781962708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04462-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":17,"alternative-id":["4462"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04462-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was conducted using anonymized data from electronic medical records. In accordance with national regulations, formal ethics committee approval was not required. The study complied with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}